<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lorenzo Canti</style></author><author><style face="normal" font="default" size="100%">Grégory Ehx</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Ariën, Kevin K</style></author></secondary-authors><tertiary-authors><author><style face="normal" font="default" size="100%">I Desombere</style></author><author><style face="normal" font="default" size="100%">Pieter Pannus</style></author><author><style face="normal" font="default" size="100%">Maria Goossens</style></author></tertiary-authors><subsidiary-authors><author><style face="normal" font="default" size="100%">Stéphanie Humblet-Baron</style></author><author><style face="normal" font="default" size="100%">Heyndrickx, Leo</style></author><author><style face="normal" font="default" size="100%">Aurélie Henry</style></author><author><style face="normal" font="default" size="100%">Sophie Servais</style></author><author><style face="normal" font="default" size="100%">Evelyne Willems</style></author><author><style face="normal" font="default" size="100%">Stanislas Goriely</style></author><author><style face="normal" font="default" size="100%">Laurence Seidel</style></author><author><style face="normal" font="default" size="100%">Johan Michiels</style></author><author><style face="normal" font="default" size="100%">Betty Willems</style></author><author><style face="normal" font="default" size="100%">Yves Beguin</style></author><author><style face="normal" font="default" size="100%">Arnaud Marchant</style></author><author><style face="normal" font="default" size="100%">Frédéric Baron</style></author></subsidiary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Antibody response against SARS-CoV-2 Delta and Omicron variants after third-dose BNT162b2 vaccination in allo-HCT recipients.</style></title><secondary-title><style face="normal" font="default" size="100%">Cancer Cell</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Antibody Formation</style></keyword><keyword><style  face="normal" font="default" size="100%">BNT162 Vaccine</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style  face="normal" font="default" size="100%">Vaccination</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2022 Apr 11</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">40</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><issue><style face="normal" font="default" size="100%">4</style></issue></record></records></xml>